Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides.

Sun G, Berthelot C, Li Y, Glass DA 2nd, George D, Pandya A, Kurzrock R, Duvic M.

J Am Acad Dermatol. 2009 Feb;60(2):231-5. doi: 10.1016/j.jaad.2008.09.063. Epub 2008 Nov 20.

PMID:
19026464
2.

Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.

Desai M, Liu S, Parker S.

J Am Acad Dermatol. 2015 Feb;72(2):276-85. doi: 10.1016/j.jaad.2014.10.019. Epub 2014 Nov 17.

PMID:
25458019
3.

Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT.

Arch Dermatol. 2003 Jul;139(7):857-66.

PMID:
12873880
4.

Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ.

J Clin Oncol. 2010 Nov 1;28(31):4730-9. doi: 10.1200/JCO.2009.27.7665. Epub 2010 Sep 20.

PMID:
20855822
5.

Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides.

Delfau-Larue MH, Dalac S, Lepage E, Petrella T, Wechsler J, Farcet JP, Bagot M.

Blood. 1998 Nov 1;92(9):3376-80.

6.

Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.

Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J.

Arch Dermatol. 2008 Jun;144(6):738-46. doi: 10.1001/archderm.144.6.738.

PMID:
18559762
7.

Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.

Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT.

Arch Dermatol. 1996 Nov;132(11):1309-13.

PMID:
8915308
8.

Mycosis fungoides--a review of the management of 28 patients and of the recent literature.

Lenane P, Powell FC, O'Keane C, Dervan P, O'Sullivan D, Bourke E, O'Loughlin S.

Int J Dermatol. 2007 Jan;46(1):19-26. Review.

PMID:
17214715
9.

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.

Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, Carlotti A, Franck N, Dechelotte P, Souteyrand P, Courville P, Joly P, Delaunay M, Bagot M, Grange F, Fraitag S, Bosq J, Petrella T, Durlach A, De Mascarel A, Merlio JP, Wechsler J.

Blood. 2000 Apr 1;95(7):2212-8. Review.

10.

Mycosis fungoides with onset before 20 years of age.

Zackheim HS, McCalmont TH, Deanovic FW, Odom RB.

J Am Acad Dermatol. 1997 Apr;36(4):557-62.

PMID:
9092741
12.

Transformed mycosis fungoides: clinicopathological features and outcome.

Barberio E, Thomas L, Skowron F, Balme B, Dalle S.

Br J Dermatol. 2007 Aug;157(2):284-9. Epub 2007 Jun 15.

PMID:
17573879
13.

Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.

Fraser-Andrews EA, Mitchell T, Ferreira S, Seed PT, Russell-Jones R, Calonje E, Whittaker SJ.

Br J Dermatol. 2006 Oct;155(4):756-62.

PMID:
16965425
14.

Prognostic factor analysis in mycosis fungoides/Sézary syndrome.

Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R.

J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24.

PMID:
10365922
15.

Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study.

Wain EM, Orchard GE, Whittaker SJ, Spittle M Sc MF, Russell-Jones R.

Cancer. 2003 Nov 15;98(10):2282-90.

16.

Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R.

Blood. 1998 Aug 15;92(4):1150-9.

17.

Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008.

Nath SK, Yu JB, Wilson LD.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):419-23. doi: 10.1016/j.clml.2013.12.018. Epub 2014 Jan 3.

18.

Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.

Herro E, Dicaudo DJ, Davis MD, Weaver AL, Swanson DL.

J Am Acad Dermatol. 2009 Aug;61(2):271-5. doi: 10.1016/j.jaad.2009.03.033. Epub 2009 May 28.

PMID:
19481294
19.

Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.

Quaglino P, Pimpinelli N, Berti E, Calzavara-Pinton P, Alfonso Lombardo G, Rupoli S, Alaibac M, Bottoni U, Carbone A, Fava P, Fimiani M, Mamusa AM, Titli S, Zinzani PL, Bernengo MG; Gruppo Italiano Linfomi Cutanei.

Cancer. 2012 Dec 1;118(23):5830-9. doi: 10.1002/cncr.27627. Epub 2012 Jun 6.

20.

Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer.

Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG.

Cancer. 2008 Nov 1;113(9):2565-74. doi: 10.1002/cncr.23881.

Supplemental Content

Support Center